NEW YORK (GenomeWeb News) – Epigenomics today announced Companion Dx Reference Labs has obtained the rights to establish and commercialize a colorectal cancer test using the methylated Septin9 biomarker.

Under the terms of the deal, Companion Dx will be able to use Epigenomics' biomarker to create a blood-based, laboratory developed test, while Epigenomics is entitled to double-digit royalties on sales of the test. Other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.